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Abstract
Background: Our understanding of signal transduction networks in the physiological context of an organism remains
limited, partly due to the technical challenge of identifying serine/threonine phosphorylated peptides from complex tissue
samples. In the present study, we focused on signaling through the mammalian target of rapamycin (mTOR) complex 1
(mTORC1), which is at the center of a nutrient- and growth factor-responsive cell signaling network. Though studied
extensively, the mechanisms involved in many mTORC1 biological functions remain poorly understood.
Methodology/Principal Findings: We developed a phosphoproteomic strategy to purify, enrich and identify
phosphopeptides from rat liver homogenates. Using the anticancer drug rapamycin, the only known target of which is
mTORC1, we characterized signaling in liver from rats in which the complex was maximally activated by refeeding following
48 hr of starvation. Using protein and peptide fractionation methods, TiO2 affinity purification of phosphopeptides and
mass spectrometry, we reproducibly identified and quantified over four thousand phosphopeptides. Along with 5 known
rapamycin-sensitive phosphorylation events, we identified 62 new rapamycin-responsive candidate phosphorylation sites.
Among these were PRAS40, gephyrin, and AMP kinase 2. We observed similar proportions of increased and reduced
phosphorylation in response to rapamycin. Gene ontology analysis revealed over-representation of mTOR pathway
components among rapamycin-sensitive phosphopeptide candidates.
Conclusions/Significance: In addition to identifying potential new mTORC1-mediated phosphorylation events, and
providing information relevant to the biology of this signaling network, our experimental and analytical approaches indicate
the feasibility of large-scale phosphoproteomic profiling of tissue samples to study physiological signaling events in vivo.
Citation: Demirkan G, Yu K, Boylan JM, Salomon AR, Gruppuso PA (2011) Phosphoproteomic Profiling of In Vivo Signaling in Liver by the Mammalian Target of
Rapamycin Complex 1 (mTORC1). PLoS ONE 6(6): e21729. doi:10.1371/journal.pone.0021729
Editor: Michael Polymenis, Texas A&M University, United States of America
Received April 21, 2011; Accepted June 7, 2011; Published June 28, 2011
Copyright:  2011 Demirkan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by USPHS grants R01HD024455 (to P.A.G.), and 1R01AI083636, 2P20RR015578 and R21AI083908 (to A.R.S.). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Philip_Gruppuso@brown.edu
Introduction
The mammalian target of rapamycin (mTOR) is a well
conserved serine/threonine kinase that plays a key physiological
role in the control of cell growth [1]. mTOR is a component of
two distinct multiprotein complexes [2–4]. mTOR complex 1
(mTORC1) regulates temporal control of cell growth while
mTOR complex 2 (mTORC2) regulates the organization of the
actin cytoskeleton. mTORC1 signaling is sensitive to rapamycin, a
macrolide antibiotic and anti-cancer drug, whereas mTORC2
mediates rapamycin-insensitive signaling [5]. mTORC1 signaling
is stimulated by nutrients, growth factors, and high levels of
cellular energy. In addition to the inhibitory effect of rapamycin,
mTORC1 signaling is downregulated by environmental stressors,
such as hypoxia and low cellular energy levels. Activation of
mTORC1 leads to increased ribosome biogenesis, translation and
nutrient transport, and to repression of autophagy and stress-
induced transcription [1,6].
The constituents of mTORC1 include mTOR, raptor,
mLST8/G-protein b-subunit like protein (GbL), Proline-Rich
Akt Substrate of 40 kDa (PRAS40), and Deptor [7]. This
signaling complex exerts at least some of its biological effects by
phosphorylating p70 ribosomal protein S6 kinase (S6K) at a
single site, and eukaryotic initiation factor 4E (eIF4E) binding
protein 1 (4E-BP1) at multiple sites. mTORC1 phosphorylation
of critical residues involved in the activation of S6K1 (Thr389)
and 4E-BP1 (Thr37 and Thr46) are generally sensitive to the
inhibitory effects of rapamycin [8,9]. Activated S6K1 functions
in vivo to phosphorylate the 40S ribosomal protein S6, the
biological significance of which is uncertain [10]. The
phosphorylation of 4E-BP1 promotes its dissociation from
eIF4E, thus activating 59-cap-dependent mRNA translation, a
process that accounts for the majority of total cellular translation
[11–13]. Though much research has been devoted to under-
standing the mTORC1 pathway, the mechanisms underlying
many of its biological functions remain poorly understood. It is
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unidentified [1,3,12–16].
In the present study, we have utilized a well characterized
model of mTORC1 activation in vivo, fasting followed by refeeding
in the laboratory rat [17,18]. During a period of food deprivation
lasting 48 hours, liver mass and protein content decrease by
approximately one quarter and one third, respectively. Within one
hour of refeeding, marked mTORC1 activation occurs. Rapamy-
cin injection prior to refeeding prevents this activation [18]. While
several groups have undertaken phosphoproteomic profiling of
liver tissue [19–23], none have used this approach to investigate
rapamycin-sensitive phosphorylation events in vivo.
Recent advances in the technology of mass spectrometry (MS)
permit the wide-scale analysis of cell signaling events. A number of
studies have focused on tyrosine phosphorylation, an approach
that has benefited from the ability to enrich for tyrosine
phosphorylated peptides using peptide immunoprecipitation with
anti-phosphotyrosine antibodies [24–26]. While equivalent anti-
bodies for phosphoserine and phosphothreonine have been
employed previously [27], these antibodies did not prove useful
for profiling protein phosphorylation in a highly complex sample.
Our goal of profiling mTORC1 signaling required that we
refine and adapt available methods, and establish the reproduc-
ibility of our analyses. We combined several standard methods for
protein and peptide fractionation to reduce sample complexity,
thereby improving the sensitivity of the MS analysis [22,28]. We
also employed a newer strategy, the enrichment of phosphopep-
tides by using metal oxide chromatography (MOC). In this
approach, phosphorylated peptides are enriched based on their
affinity for metal oxides such as zirconium dioxide [29], titanium
dioxide [30] or aluminum hydroxide [31]. Our studies used the
more recently developed methodology of titanium dioxide (TiO2)
chromatography in the presence of lactic acid and 2,5-dihydroxy
benzoic acid (DHB) [32–34].
Phosphoproteomic studies that have focused on signal
transduction have largely been conducted using cell lines, and
quantification of the greatest number of phosphorylation changes
has been given primary importance over reproducibility of
analysis. As an alternative to quantitative methods that employ
isotope labeling, some investigators have employed ‘‘label-free’’
quantitation [35]. However, data on the validity of this method
for tissue analysis are very limited. We therefore took the
approach of analyzing multiple technical and biological replicate
samples using a phosphoproteomic platform that employs
automated desalting and reversed-phase separation of peptides
in a highly consistent and reproducible manner [36–38]. All
column elutions and loading steps are accurately replicated
through computer control [39].
Using the experimental approach described above, we were
able to identify more than three thousand unique phosphorylation
sites with high reproducibility on an LTQ-Fourier-transform ion
cyclotron resonance (FTICR) classic mass spectrometer. By
investigating the aforementioned in vivo model of mTORC1
activation and inhibition, we were able to identify a number of
well characterized mTORC1 targets as well as previously
unknown candidate phosphorylation events. Global analysis of
our data provided for a broad characterization of hepatic
mTORC1 signaling in vivo.
Methods
Materials
Rapamycin was purchased from LC Laboratories (Woburn,
MA). Antibodies directed towards ribosomal protein S6 and
phosphorylated S6 (Ser
235/236) were from Cell Signaling Tech-
nology, Inc. (Danvers, MA). Sephadex G-25 Coarse, Q
Sepharose Fast Flow, SP Sepharose Fast Flow, and Resource
15S media were purchased from GE Healthcare Bio-Sciences
Corp. (Piscataway, NJ). Sequencing grade trypsin was from
Promega Corp. (Madison, WI). Oasis HLB extraction cartridges
were from Waters Corp. (Milford, MA). The Resource S column
was purchased from GE Healthcare, Inc. (Piscataway, NJ).
Titansphere Phos-TiO kits were obtained from GL Sciences, Inc.
(Torrance, CA).
Animal Studies, and Preparation and Processing of Liver
Homogenates
Adult male Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA) were used for all studies. In order to maximally
activate signaling through mTORC1 [17], rats were fasted for
48 hr, at the end of which time they were administered vehicle
(dimethyl sulfoxide; DMSO) or rapamycin (50 mg/g body weight)
by intraperitoneal injection. Fifteen minutes after injection, a 1 hr
refeeding period was initiated by replacing the food in their cages.
All rats were sacrificed by exsanguination under pentobarbital
sodium anesthesia (50 mg/g by intraperitoneal injection). Livers
were flash-frozen in liquid nitrogen and stored at 270uC until use.
Three rats per condition were studied. All animal studies were
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of Rhode Island
Hospital (CMTT# 0066-10).
Rat liver homogenates were prepared in 10 ml/g wet weight of
Buffer A (50 mM b-glycerophosphate, pH 7.4, 150 mM NaCl,
100 mM sodium orthovanadate, 10 mM NaF, 1 mM EGTA, and
5 mM EDTA) using a glass/Teflon homogenizer (7 strokes at
700 rpm). Homogenates were centrifuged at 1,0006g for 15 min.
Supernatants were removed and centrifuged at 100,0006 g for
1 hr. The resulting pellets were discarded. The supernatants
retained and stored at 270uC.
Subsequent sample preparation was carried out at 4uC. Upon
thawing, homogenate (9 ml) was mixed with 18 ml of Buffer B
(150 mM NaCl, 100 mM sodium orthovanadate, 10 mM NaF,
1 mM EGTA, 5 mM EDTA). The diluted homogenate (25 ml)
was applied to a 60 ml Sephadex G-25 Coarse column
equilibrated in Buffer C (10 mM Tris, pH 8.6, 100 mMs o d i u m
orthovanadate, 10 mM NaF, 0.5 mM EGTA, 2 mM EDTA).
The column was eluted with 60 ml Buffer C. Fractions
containing protein were collected and stored at 270uCu n t i l
further analysis.
In order to fractionate homogenates into multiple samples for
further analysis, strong anion exchange (SAX) separation was
carried out on the gel filtered sample (50 mg protein) using a
9.4 mm625 mm column packed with Q Sepharose Fast Flow
beads. Following adsorption of the sample, the column was
washed at 0.8 ml/min with 5 ml of Buffer C. The flow-through
was collected. The column was then eluted stepwise at 0.8 ml/
min with 5 ml of Buffer C containing 150 mM, 300 mM or
1 M sodium chloride. The SAX flow-through was adjusted to
pH 7.3 then applied to a strong cation exchange (SCX) SP
Sepharose column (9.4 mm625 mm). The column was washed
at 0.8 ml/min with Buffer D (Buffer C adjusted to pH 7.3) and
the flow-through (30 ml) was collected. The column was then
eluted with 10 ml of Buffer D containing 1 M NaCl. This
combination of SAX and SCX chromatography yielded a total
of 5 fractions.
Phosphoproteomic Profiling of mTORC1 Signaling
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21729Peptide Preparation and Fractionation, and Purification
of Phosphopeptides
Protein concentrations in the five fractions were measured using
Bradford reagent. Samples containing 50 mg protein were
denatured by adding urea to a final concentration of 8 M and
dithiothreitol to a final concentration of 1 mM, followed by
incubation for 1 hr at 56uC. Samples were then alkylated with
iodoacetemide (final concentration, 5 mM) followed by incubation
for 1 hr at room temperature in the dark. These samples were
diluted four-fold with 10 mM Tris, pH 8.0, and incubated
overnight at 37uC with sequencing grade modified trypsin at a
1:100 protease:protein ratio. The resulting tryptic peptides were
adjusted to pH 2.7 with trifluoroacetic acid, and then cleared by
centrifugation at 10006 g for 5 min. The peptide mixtures were
desalted using Oasis HLB extraction cartridges and dried in a
SpeedVac Concentrator.
Dry peptides were reconstituted in Buffer E (5 mM ammonium
formate, pH 2.65, 30% acetonitrile) and loaded onto a 1 ml
Resource S (SCX) column equilibrated with Buffer E. The column
was eluted with a linear gradient of 5 mM to 1.5 M ammonium
formate (flow rate of 0.5 ml/min) using an ISCO ProTeam LC
chromatography system. Including the flow-through, 32 fractions
(1 ml each) were collected. The peptide content of each fraction
was estimated by measuring the absorbance at 280 nm. As
described below, two fraction pools containing the highest peptide
amounts were recovered from each chromatogram. These pools
were dried in a SpeedVac Concentrator and stored at 270uC.
For further processing, each peptide SCX pool was dissolved in
400 ml of 0.1% formic acid, 30% acetonitrile. These samples were
each separated into four 100 ml samples for the performance of
technical replicates. Phosphopeptides were enriched using Titan-
sphere Phos-TiO reagents. Adsorption proceeded according to the
manufacturer’s protocol. Phosphopeptides were eluted from the
Phos-TiO tips by first applying 25 ml of 1% ammonium hydroxide
in water. The tips were then treated with 25 ml of 1% ammonium
hydroxide in 40% acetonitrile and finally eluted with 50 mlo f5 %
pyrrolidine in water. All samples were dried in a SpeedVac
Concentrator and stored at 270uC.
Automated MS Analysis
Samples were analyzed by a fully automated phosphoproteomic
technology platform that incorporates peptide desalting and
separation via reverse phase chromatography followed by tandem
mass spectrometry with static peak parking [40]. Briefly, dry
phosphopeptide-enriched mixtures were dissolved in 0.1% acetic
acid in water and adsorbed to a C18 analytical column (360 mm
outer diameter675 mm inner diameter; fused silica with 12 cm of
5 mm Monitor C18 particles and an integrated 4 mm ESI emitter
tip fritted with 3-mm silica; Bangs Laboratories, Fishers, IN).
Samples were eluted with a gradient of 0–70% 0.1 M acetic acid
in acetonitrile that was developed over 30 min at a flow rate of
1.8 ml/min. Resulting eluates were applied directly to the mass
spectrometer (Linear Trap Quadrupole-Fourier Transform [LTQ-
FT]; Thermo Fisher Scientific, Waltham, MA). As described
previously, static peak parking was performed via flow rate
reduction from 200 nl/min to 20 nl/min once peptides began to
elute as determined from a bovine serum albumin peptide scouting
run [41]. The electrospray voltage of 2.0 kV was applied in a split
flow configuration and spectra were collected in positive ion mode
[39]. One full MS scan in the Fourier Transform (from m/z 400 to
1800) was followed by 9 data-dependent MS/MS spectra in the
linear ion trap from the 9 most abundant ions. Selected ions were
dynamically excluded for 30 s and screened for charge-states of
+1, +2 and +3. All other settings for FTMS and ion trap mass
spectrometry scans were the same as described previously [40].
Data Analysis and Peptide Quantification
Custom software was used for the analysis of all data.
Automation of database searches, statistical validation of peptide
sequence, analysis for phosphorylation site position, and uploading
to a relational database was handled by our High Throughput
Autonomous Proteomic Pipeline (HTAPP) [38]. Quantitative
proteomic data, including replicate analyses, was aggregated into
heatmap representations using our PeptideDepot software [36].
Using our HTAPP software, MS/MS spectra were automati-
cally searched against separate mouse, rat and hamster National
Center for Biotechnology Information (NCBI) non-redundant
protein databases (constructed on 7.30.2009) using the SEQUEST
algorithm provided with Bioworks 3.2 (SEQUEST v.27 rev12).
Peak lists were generated using extract_msn.exe version 4.0 using
a mass range of 600–4500, precursor ion tolerance (for grouping)
of 0.005 atomic mass unit, minimum ion count of 5, group scan of
0, minimum group count of 1. The NCBI rat, mouse and hamster
databases contained 401,138 protein entries (50% forward, 50%
reversed). SEQUEST was performed with the following param-
eters: trypsin enzyme specificity, 2 possible missed cleavages,
0.2 Da mass tolerance for precursor ions, and 0.5 Da mass
tolerance for fragment ions. Search parameters specified a
differential modification of phosphorylation (+79.9663 Da) on
serine, threonine, and tyrosine residues and a static modification of
carbamidomethylation (+57.0215 Da) on cysteine. To provide
high confidence phosphopeptide sequence assignments, SE-
QUEST results were filtered by Xcorr (+1.1.5; +2.2.0;
+3.2.5), precursor mass error (,20 ppm), and a logistic spectral
score [37] that assessed MS/MS spectral quality (.0.965),
minimum peak area threshold of 500. Non-redundant phospho-
peptides and proteins with descriptors of ‘‘unnamed’’ or
‘‘unknown’’ were removed. False discovery rate was estimated
with the decoy database approach after final assembly of
nonredundant data into a comparison file [42]. To validate the
position of the phosphorylation site, the Ascore algorithm [43] was
applied to all data. The reported phosphorylation site position
reflected the top Ascore prediction. Ascore probabilities are
reported in the full data table (Table S1).
Quantitative analysis, collation of replicates, and visualization of
proteomic data was accomplished using PeptideDepot software
[36]. In order to compare peptide abundance among replicates,
peak areas were calculated by inspection of selected ion
chromatograms (SICs) using a software programmed in Microsoft
Visual Basic 6.0 based on the Xcalibur Development Kit 2.0 SR2
(Thermo Fisher Scientific) [36]. This approach used the ICIS
algorithm available in the Xcalibur XDK with the following
parameters: multiple resolutions of 8, noise tolerance of 0.1, noise
window of 40, scans in baseline of 5, and inclusion of refexc peaks
parameter value, which is false. Retention time alignment was
performed to correct chromatographic shifts between runs. In
brief, commonly observed peptides in each pair of liquid
chromatography/mass spectrometry (LC/MS) runs were divided
into 25 groups, evenly sorted by their retention time at 1% false
discovery rate. The most abundant peptide within each group was
selected as a landmark to align two MS runs. Quantitative data
were calculated automatically for every assigned peptide in all
LC/MS runs based on exact precursor mass and retention time.
For the case in which a peptide was not confidently identified by
MS/MS spectrum in a given LC/MS experiment, its retention
time was predicted using the retention time observed in other LC/
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MS/MS spectrum after alignment correction.
A label-free comparison data file was generated for the
evaluation of phosphopeptide abundance in DMSO and rapamy-
cin treated animals (Table S1). Based on an approach in which
samples from control and rapamycin-treated animals were
processed and analyzed in parallel, all comparisons were paired.
That is, label-free ratios corresponding to peptide abundance
differences between paired control and rapamycin animals for 3
biological replicate sets were calculated. Blanks in the data
columns indicated that a clearly defined SIC peak was not
observed for that phosphopeptide in any of the technical replicate
analyses for that particular sample. The coefficient of variation was
calculated for each animal sample among the 4 technical replicate
analyses and 3 biological replicate analyses (Table S1).
A threshold for rapamycin effect was set at 5-fold. This degree
of change was based on an analysis of the control:rapamycin ratios
for all phosphopeptides (Table S2).
To classify proteins from the liver phosphoproteome and
rapamycin-sensitive candidates, gene ontology and pathway terms
were examined (www.geneontology.org) using the PeptideDepot
software [36]. Classifications were based on the gene ontology slim
terms and mapped to the Kyoto Encyclopedia of Genes and
Genomes (KEGG) Pathway Database (http://www.genome.ad.
jp/kegg/pathway.html). Phosphorylation site-specific kinase pre-




The profiling of mTORC1 signaling in liver required that we
develop and validate methods for homogenate preparation,
protein fractionation and peptide fractionation (Fig. 1). The first
step in our strategy focused on removing phospholipids from rat
liver homogenates. This was achieved by passing liver homoge-
nates through a Sephadex G-25 gel filtration column. Gel
electrophoresis and protein quantification showed greater than
90% protein recovery after this step.
In order to fractionate the sample to enhance MS phosphopep-
tide detection, ion exchange chromatography was performed
following gel filtration. First, SAX chromatography with step
elution generated a flow-through fraction and fractions containing
proteins eluted with 0.15 M NaCl, 0.3 M NaCl and 1 M NaCl.
The SAX flow-through was applied to a SCX column, resulting in
2 additional fractions, a SCX flow-through fraction and the
proteins eluted at 1 M NaCl. SDS-PAGE of the resulting ion
exchange fractions (not shown) demonstrated distinct patterns of
protein expression. As intended, protein content of the five
fractions was similar.
The five ion exchange fractions were digested with trypsin. The
resultant peptides were desalted by solid-phase extraction and then
further separated by peptide SCX chromatography (Fig. 2, Upper
Panel). Two fraction pools containing the highest peptide amounts
were collected from each column run. Each peptide SCX pool was
separated into 4 samples for the performance of technical
replicates. Phosphopeptides were enriched from each of these
replicate pools by TiO2 affinity purification.
The efficacy of the peptide SCX chromatography was
examined by comparing the phosphopeptides present in peak 1
versus peak 2. Since each phosphate group subtracts a net charge
of 1 from a peptide at pH 2.65, we expected phosphorylated
peptides to elute before non-phosphorylated peptides [44]. MS
analysis confirmed that fractions from SCX peak 1 were highly
enriched with phosphopeptides and successfully separated from
the more complex, positively-charged, multivalent peptides that
eluted in the second SCX peak (Fig. 2, Lower Panel). Following
TiO2 chromatography, but prior to filtering of MS results for non-
phosphorylated peptides, more than 90% of the peptides
recovered from SCX peak 1 were phosphorylated. In comparison,
the yield of phosphopeptides from SCX peak 2 was approximately
60%. Most importantly, this chromatography step further reduced
the complexity of the samples for MS analysis.
The use of TiO2 affinity phosphopeptide enrichment was based
on previous studies demonstrating its high phosphopeptide
selectivity [30,33]. TiO2 enrichment using loose TiO2 beads in
the presence of 2,5-dihydroxybenzoic acid [30] provided for a
modest improvement in phosphopeptide enrichment relative to
initial analyses using Fe
3+ immobilized metal affinity chromatog-
raphy (IMAC). The lactic acid-treated Titansphere Phos-TiO kit
was tested based on a report that it yields superior results [45]. A
pyrrolidine solution along with 1% ammonium hydroxide solution
[46] was also employed to further improve the efficiency of
phosphopeptide elution from TiO2 beads.
Phosphopeptide enriched samples were analyzed by LC/MS as
described above. The resulting MS/MS spectra (can be accessed
at http://cellpathway.com/SupplementalMaterial3.zip and http://
cellpathway.com/SupplementalMaterial4.zip) were searched against
the mouse,hamster and rat subsets of NCBI non-redundant databases
using the SEQUEST algorithm. Sequence assignments were made
using stringent filtering criteria (logistic spectral score .0.965 [36,40];
precursor mass error,20 ppm; minimum SIC peak area threshold of
500 for label-free quantitation). After filtering, the false discovery rate,
estimated using a decoy database [20,37], was 1%.
The final data set derived from three biological control
replicates contained 3,231 nonredundant phosphorylation sites
representing 1,400 proteins and derived from 4,238 phosphopep-
tides. To assess the reproducibility of our phosphopeptide
enrichment strategy in the context of in vivo studies, we compared
LC/MS runs from these three control biological replicates as well
as four technical replicates within each biological replicate. LC/
MS retention time alignments of multiple datasets were carried out
to correct for chromatographic shifts between experiments using
the PeptideDepot software. Eighty-two percent of the phospho-
peptides were identified in all three control biological replicates.
Only 13% and 5% of the phosphopeptides were identified in two
and one of the control biological replicates, respectively. Analysis
of technical replicates demonstrated that, on average, 40% of the
phosphopeptides were identified in all four technical replicates in a
given biological sample, while 27%, 20% and 13% of the
phosphopeptides were identified in three, two and one of the
technical replicates, respectively. Thus, the performance of the
four technical replicates contributed greatly to the reproducibility
of the biological replicates.
To evaluate the sensitivity of our method for relatively low
abundance phosphopeptides, we examined the relationship
between peak area and the probability of a phosphopeptide being
detected in one, two or all three of the biological replicates. Results
(not shown) confirmed that more abundant phosphopeptides were
indeed identified with greater reproducibility.
The Rat Liver Phosphoproteome
To characterize the rat liver phosphoproteome from animals in
which hepatic signal transduction was nutrient-activated, we
compiled a list of all identified phosphorylation sites generated
by analysis of the six combined control and rapamycin-treated
animals. A total of 3,234 unique phosphorylation sites representing
1,401 proteins and 4,241 phosphopeptides were identified from
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(2,762 sites representing 85% of all phosphorylation sites). Serine
sites were followed in abundance by threonine phosphorylation
(415 sites; 13%) and tyrosine phosphorylation (57 sites; 2%). Close
to certainty (.99%) of phosphorylation site localization was
achieved for 71% of the data set (3,011 of 4,241 phosphopeptides).
All phosphopeptides with ambiguous site assignments (Ascore
,19) [43] are presented in a separate table (Table S1).
Rapamycin-regulated Phosphorylation Events
Prior to performing the phosphoproteomic analysis, the efficacy of
rapamycin administration was assessed by phospho-specific Western
immunoblotting for ribosomal protein S6 (Ser235 and Ser236) [18].
Results (Fig. 3) showed a greater than 10-fold reduction in animals
that were administered rapamycin prior to refeeding.
To identify rapamycin-modulated phosphorylation events
involving soluble proteins from rat liver, we compared the results
derived from animals that received DMSO vehicle versus
rapamycin prior to refeeding. The magnitude of the phosphory-
lation change for each phosphopeptide in each paired analysis was
determined using PeptideDepot software to generate mean peak
area ratios. An analysis of the number of peptides showing graded
degrees of change [47] showed an inflection point between 4-fold
and 5-fold (Table S2 and Fig. 4). Similar to the approach taken by
Chen et al. [48], we used this information to assign a conservative
threshold of a 5-fold change as indicating an effect of rapamycin.
That is, we applied a cutoff of .5o r,0.2 (ratio of
control:rapamycin) for sites whose abundance decreased or
increased, respectively. Using these criteria, we identified 67
unique sites that were altered in response to rapamycin out of the
total of 3,234 sites identified.
Of these 67 sites, 5 have been previously reported as
downstream from mTORC1. These include Maf1 (Ser75) and
raptor (Ser863), both of which were identified only recently
[49,50]. The other three rapamycin-sensitive sites were identified
on the established mTORC1 downstream target, ribosomal
protein S6. Consistent with immunoblotting results, S6 phosphor-
ylation at Ser235 and Ser236 was reduced at least 10-fold in
response to rapamycin in all three paired samples.
An unexpected observation was that the 62 phosphorylation
sites not previously identified as rapamycin-sensitive were both up-
regulated and down-regulated in association with rapamycin
administration. Twenty-nine phosphorylation sites were reduced
in abundance at least 5-fold following rapamycin administration
(Table 1), while the other 33 rapamycin-sensitive phosphorylation
sites were increased at least 5-fold in samples in response to
rapamycin (Table 2). No tyrosine phosphorylated sites were
identified as rapamycin-regulated.
Several phosphorylation events were particularly noteworthy.
Phosphorylation of AMP kinase 2 (AMPK2, Ser377), eukaryotic
initiation factor 3a (eIF3a; Ser584), metastasis suppressor 1
(Ser667), protein kinase C beta (Ser660), and PRAS40 (Ser203,
Ser213) were down-regulated in response to rapamycin. The
protein kinase C beta site has been shown to regulate the cellular
localization of this kinase [51]. Ser 363 on p90 S6 kinase 1, which
was up-regulated, is one of the known, multiple phosphorylation
sites required for activation of this kinase [52]. In addition,
PRAS40 (Ser213) was previously shown to be phosphorylated by
mTORC1 in vitro. However, phosphorylation of this site was
shown not to be sensitive to rapamycin treatment in vivo by using
mutated PRAS40 protein in HEK293 cells [53]. The remaining
phosphorylation sites have not been characterized with regard to
Figure 1. Experimental approach for the phosphoproteomic profiling of liver homogenates. Six rats were fasted for 48 hr, and then
injected with DMSO or rapamycin. A 1 hr refeeding period was initiated 15 min after injection. As shown in this flow diagram, tissue homogenates
were processed by sequential gel filtration, SAX and SCX chromatography. Samples were then reduced, alkylated, and digested into peptides. Tryptic
peptides were desalted using Oasis HLB cartridges and further separated into two fraction pools by SCX chromatography. Phosphopeptides were
then enriched by TiO2 chromatography. Purified phosphopeptides were analyzed by reversed-phase LC-MS/MS.
doi:10.1371/journal.pone.0021729.g001
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previously to interact with mTORC1 [54–56].
Gene Ontology and Pathway Analysis
We profiled the proteins identified in the phosphoproteomic
analysis from control rat livers and compared this dataset to the
phosphoproteins affected by rapamycin administration. To further
characterize rapamycin action in liver, we used the Gene
Ontology metadata in the Human Protein Reference Database
(HPRD) [57]. For this analysis of rapamycin effect, we broadened
the array of phosphoproteins by including those whose phosphor-
ylation state changed by .5-fold in two of three biological
replicates and at least 3-fold in the third replicate. This led to the
categorization of 81 rapamycin-regulated candidate proteins.
Categorization of the rapamycin-responsive phosphoproteome
for biological processes (Fig. 5, top panel) showed that 10.5% of the
rapamycin-responsive candidate proteins were involved in the
regulation of transcription, 7% in oxidation reduction, and 4.7%
in translation. In the whole rat liver phosphoproteome, the same
biological processes were similarly ascribed to 9.4%, 2.7%, and
2.0%, respectively. Categorization of phosphoproteins by cellular
localization (Fig. 5. third panel) showed significant under-represen-
tation of the ‘‘mitochondrion’’ category among rapamycin-
sensitive phosphoproteins. Categorization by molecular processes
of all phosphoproteins detected (Fig. 5, second panel) showed
dominance of ‘‘protein binding.’’ There were no significant
differences when compared to the distribution of phosphoproteins
that were affected by rapamycin.
KEGG Pathway analysis demonstrated that the phosphorylated
proteins in the whole proteomic analysis were involved in 200
different pathways, including the insulin signaling pathway,
pathways in cancer, and the mitogen-activated protein kinase
(MAPK) signaling pathway. However, the set of rapamycin-
sensitive proteins showed a significant over-representation of
mTOR pathway constituents, which was the second most highly
represented category after the insulin signaling pathway (Fig. 5,
bottom panel). Based on the KEGG pathway analysis, the
constituents of the mTOR pathway that were affected by
rapamycin included raptor, ribosomal protein S6, AMP kinase
2, and the eukaryotic initiation factor eIF4b. Also included was
p90S6 kinase 1, a component of the Erk signaling pathway that
Figure 2. Phosphopeptide enrichment by SCX Chromatogra-
phy. Upper Panel: Peptide SCX chromatography separation at pH 2.65
of a liver homogenate fraction. Digested peptides (10 mg) were applied
to a Resource S SCX column and eluted using a 5 mM to 1.5 M
ammonium formate gradient. The peptide content of each fraction was
estimated by measuring the absorbance at 280 nm. Two fraction pools
containing the highest peptide amounts (Peaks 1 and 2) were
recovered from each column run. The figure shows a representative
result using the 300 mM NaCl SAX fraction of the control 1 liver sample.
Lower Panel: The number of phosphopeptides identified from peak 1
(filled bars) versus peak 2 (unfilled bars) is shown as a function of
whether those phosphopeptides contained one, two or three
phosphorylation sites.
doi:10.1371/journal.pone.0021729.g002
Figure 3. Demonstration of rapamycin in vivo effect. Extracts
were prepared using liver samples from three control (C) and three
rapamycin-treated (R) rats. The extracts (80 mg protein per lane) were
analyzed by direct immunoblotting for phosphorylated ribosomal
protein S6 (P-S6) and total S6.
doi:10.1371/journal.pone.0021729.g003
Figure 4. Distribution of rapamycin-induced fold-change in
phosphopeptide abundance. For each peptide identified in all three
control samples, fold-change in response to rapamycin was determined
to be the minimum fold-change among the three paired analyses
generated for each phosphopeptide. The graph shows the number of
peptides in categories ranging from less than 1.1-fold different to 40-
fold different or greater.
doi:10.1371/journal.pone.0021729.g004
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talk between pathways [51].
To further characterize candidate phosphorylation sites that
were altered in response to rapamycin, we used Kinexus’
PhosphoNET kinase predictor software (Table 3). In the human
homologues of rat proteins, corresponding conserved phospho-
sites were searched. Sites on AMPK2 (Ser377), PRAS40
(Ser213), protein kinase C beta (Ser660) and raptor (Ser863),
all of which were down-regulated in association with rapamycin
administration, were strongly predicted to be targets of mTOR
kinase. eIF3a (Ser584), hepatoma-derived growth factor 3
(Ser450), and PTPRF interacting protein (liprin) alpha 1
(Ser667) were predicted to be phosphorylated by p70S6 kinase.
Two members of the phosphoinositide-3-kinase-related kinase
family (of which mTOR is a member), ATM kinase and ATR
kinase, were predicted to phosphorylate Bcl2-associated atha-
nogene 3 (Ser174), Maf1 (Ser75) and peroxisome biogenesis
factor 1 (Ser1181).
Discussion
In recent years, several groups have performed comprehensive
tissue phosphoproteome analyses [19–23,58–60]. The animal
tissue most often used for phosphoproteome analysis has been liver
[19–23]. The first such study, performed by Jin et al. [19], utilized
iron IMAC for the enrichment of phosphorylated peptides and
conventional linear ion-trap mass spectrometry (LTQ) for the
phosphopeptide analysis. These investigators identified 26 nonre-
dundant phosphorylation sites. A subsequent study [20] utilized
high capacity iron IMAC and a higher mass accuracy MS Q-TOF
instrument to identify 339 non-redundant phosphorylation sites
from over 200 proteins. The analyses performed by Villen et al. in
2007 [21] was a breakthrough study. These investigators identified
5,635 nonredundant phosphorylation sites from 2,149 proteins,
signifying the first in-depth global analysis of phosphopeptides
from liver. Notably, these investigators used more selective iron
IMAC beads and MS instruments of higher mass accuracy (the
Table 1. Phosphorylation sites down-regulated in response to rapamycin.
Protein name Gene Symbol Phosphosite C/R Ratio 1 C/R Ratio 2 C/R Ratio 3
AKT1 substrate 1 (PRAS40) isoform CRA_d AKT1S1 S203/S213 79 9 .100
AMP-activated protein kinase alpha-2 PRKAA2 S377 22 96 109
Autophagy-related protein 2 homolog A (rCG47388) ATG2A S1243 16 38 218
Bcl2-associated athanogene 3 BAG3 S174 12 .100 6
Carbomyl-phosphate synthase 2 CAD S1859 9 .100 .100
Delta-4-3-ketosteroid 5-beta-reductase AKR1D1 S235 .100 .100 .100
Eukaryotic translation initiation factor 3A (ZH12 protein) EIF3A S584 .100 .100 .100
Fam65a protein FAM65A S450 12 59 5
Family with sequence similarity 126, member B FAM126B T306 6 17 13
Growth factor receptor binding protein 7 GRB7 S364 21 .100 .100
Hepatoma-derived growth factor 3 (HDGF2) HDGFRP2 S450 65 77 7
Liver regeneration-related protein LRRG07 AKR1C13 S129 7 14 8
MAF1 (Repressor of RNA polymerase III transcription) MAF1 S75 11 29 37
mCG147067 protein [Mus musculus] N/A S76 .100 32 83
Metastasis suppressor 1, isoform CRA_a MTSS1 S667 12 12 93
Peroxisome biogenesis factor 1 PEX1 S1181 7 8 30
Protein kinase C beta II PRKCB S660 80 21 14
Protocadherin alpha 4 homolog PCDHA4 S145 .100 53 .100
PTPRF interacting protein (liprin) alpha 1 PPFIA1 S667 .100 14 12
Raptor RPTR S863 5 21 17
rCG21490, isoform CRA_a (LOC687565 protein) LOC687565 T74 17 .100 .100
rCG50767 (Similar to La-related protein 4) LOC683071 S379 26 .100 .100
Ribosomal protein S6 RPS6 S235/S236 .100 .100 .100
Ribosomal protein S6 RPS6 S235/S236/S240 .100 21 .100
Ribosomal protein S6 RPS6 S236/S240 51 87 .100
Similar to AI661453 protein (C6orf132) RGD1561662 S680 5 9 49
Similar to hypothetical protein 4933430I17 LOC500475 S5S6 .100 .100 .100
Sugen Kinase 269 (hypothetical protein XP_236266) RGD1312026 S281 .100 .100 .100
Ubiquitin specific peptidase 15, isoform CRA_a USP15 S244 35 79 77
Ubiquitin specific peptidase 15, isoform CRA_a USP15 S242 31 84 44
Ubiquitin specific protease 24 USP24 S1138 .100 27 21
WASH complex subunit FAM21 (NP61201) FAM21C S744 40 10 12
doi:10.1371/journal.pone.0021729.t001
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However, it is likely that the SCX pre-fractionation of tryptic
peptides was a critical factor accounting for the increase in
phosphopeptide identification.
Lack of reproducibility has been an issue with large scale MS-
based phosphoproteomic profiling. Moser and White [20] tested
the reproducibility of their methodology by performing three
replicate analyses of the same rat liver homogenate. They
observed that 56–63% (131 out of 207–234) of the peptides from
each analysis were observed in all three analyses. Another issue is
method of analysis. Alcolea et al. [61] found that analyzing the
same phosphopeptide enriched murine NIH/3T3 fibroblast lysate
by two different LC-MS/MS platforms based on Q-TOF and
LTQ-Orbitrap mass spectrometers led to identification of partially
overlapping, but also distinct, phosphoproteome profiles. The Q-
TOF based platform resulted in 1,485 non-redundant phospho-
peptide identifications, whereas the LTQ-Orbitrap based platform
identified 4,308 non-redundant phosphopeptides. Only 1,077 of
the total population of phosphopeptides were detected by both
platforms. Analyzing duplicate samples by LC-MS/MS on the
LTQ-Orbitrap platform showed that ,70% of the identified
phosphopeptides were identical. In a study comparing the peptides
identified using two workflows, TiO2-SCX and SCX-TiO2, the
overlap was 58 and 51% for the two methods, respectively [62]. A
similar overlap of 60% was observed, when they performed
replicate LC-MS/MS analyses of the same TiO2-SCX sample by
an LTQ-Orbitrap.
These previous studies profiling the liver phosphoproteome
have not been aimed at characterizing signaling events in a
physiological context. Accomplishing this required improved
sensitivity and accuracy, and a demonstration of reproducibility.
We found that peptide abundance affects reproducibility, but that
reproducibility could be enhanced by the performance of technical
replicates. There are several indications that our methods were
sufficient to detect mTORC1-mediated protein phosphorylation.
These included the identification of known mTORC1 targets, the
significant enrichment for mTOR signaling pathway constituents
as indicated by pathway analysis, and the kinase prediction results.
In their seminal studies, Hunter and Sefton reported the relative
abundances of pSer, pThr, and pTyr to be 90%, 10%, and 0.05%,
Table 2. Phosphorylation sites up-regulated in response to rapamycin.
Protein name Gene Symbol Phosphosite C/R Ratio 1 C/R Ratio 2 C/R Ratio 3
Acyl-CoA thioesterase 1 ACOT1 S416 0.03 0.06 0.16
Ajuba protein JUB S147 ,0.01 0.04 0.09
Arginase 1, liver ARG1 T281 ,0.01 0.01 0.01
Argininosuccinate synthetase ASS1 T219 0.08 0.03 0.2
Carbohydrate responsive element binding protein MLXIPL S516 0.17 0.12 0.2
Cytosolic 3-hydroxy 3-methylglutaryl coenzyme A synthase HMGCS1 S516 0.05 0.1 0.15
Cytosolic malate dehydrogenase MDH1 (S188/S189) ,0.01 0.04 0.13
ERM-binding phosphoprotein (NHERF) SLC9A3R1 S287T290/S291 0.07 ,0.01 ,0.01
Estrogen receptor-binding site associated antigen 9 EBAG9 S36 ,0.01 0.07 0.02
Family with sequence similarity 83, member H FAM83H S871 0.01 0.15 0.1
GABA-B receptor-interacting scaffolding protein AKAP9 S104 ,0.01 0.08 0.11
GAPDH - Glyceraldehyde-3-phosphate dehydrogenase GAPDH T182 0.11 0.14 0.03
Gephyrin GPHN S200 ,0.01 0.08 0.05
Inositol polyphosphate 5-phosphatase (Sec16 hom. A) INNP5E S711 ,0.01 0.14 0.19
JTV1 protein (Aimp2) AIMP2 T35 0.03 ,0.01 ,0.01
l-Afadin (AF6) MLLT4 S1804 0.03 0.06 0.14
La ribonucleoprotein domain family, member 1 LARP1 S648 ,0.01 0.19 0.2
La ribonucleoprotein domain family, member 1 LARP1 T644 0.01 0.19 0.2
Liver regeneration-related protein LRRG07 AKR1C13 S232 ,0.01 0.13 0.08
Nuclear factor 1/A NFIA S280 0.06 0.02 0.03
Phosphoglucomutase 1 PGM1 T115 ,0.01 ,0.01 0.05
Phosphoglucomutase 1 PGM1 S117 ,0.01 ,0.01 0.03
Phosphoglycerate kinase 1 PGK1 S203 ,0.01 0.1 0.01
Plakophilin 4 PKP4 S335 ,0.01 0.14 0.14
rCG23015, isoform CRA_a [Rattus norvegicus] [107894 Da] N/A S356 0.01 0.06 0.03
rCG35745 (LOC679383 protein) LOC679383 S469 0.17 ,0.01 ,0.01
Ribonuclease UK114 (perchrolic acid soluble protein) HRSP12 S11 0.03 0.1 0.01
Ribonuclease UK114 (perchrolic acid soluble protein) HRSP12 T10 ,0.01 ,0.01 ,0.01
Ribosome binding protein 1 RRBP1 S1203 ,0.01 0.18 ,0.01
S6 protein kinase (p90-RSK1) RPS6KA1 S363 0.04 0.15 0.05
Stromal interaction molecule 1 STIM1 S519 0.01 0.2 0.02
doi:10.1371/journal.pone.0021729.t002
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PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21729Figure 5. Gene ontology distribution of phosphoproteins in the total phosphoproteome and the rapamycin-responsive
phosphoproteome. Distributions of the whole rat liver phosphoproteome are shown to the left for each analysis while the distributions of the
phosphoproteins that were altered in response to rapamycin are shown on the right. The most abundant ten GO categories for each analysis are
presented. Except where noted, an asterisk denotes a category that was significantly over-represented among rapamycin-sensitive candidate
phosphoproteins as determined by chi-square analysis. Each category is followed by the number of genes identified in that category and the
percentage of the total number of genes that were categorized for that analysis. For the cellular localization analysis, nine categories are presented
for the rapamycin-responsive dataset since the same percentage values existed for the tenth and for all remaining categories. The asterisk denoting a
whole phosphoproteome category indicates one that was significantly over-represented in that dataset. For the KEGG pathway categories, nine
categories instead of ten are presented for the rapamycin-responsive dataset because the same percentage values were obtained for the tenth and
multiple other categories.
doi:10.1371/journal.pone.0021729.g005
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phosphorylation frequency in our results may be a function of
the tendency for pTyr-containing peptides to yield better quality
MS/MS spectra with collision-induced dissociation fragmentation.
In contrast, phosphoserine and phosphothreonine containing
peptides may produce low scores due to fragmentation patterns
dominated by neutral loss of phosphate [21]. We are left to
conclude that the actual proportion of protein phosphorylation
accounted for by pTyr is between 0.05% and 2%, but likely
toward the lower end of this range.
Two groups have recently reported large-scale, MS-based
analysis of TORC1-dependent protein phosphorylation events
[35,48]. Chen et al. [48] used epidermal growth factor-induced
HeLa cell cultures and employed the use of stable isotope labeling
in cell culture (SILAC) to achieve quantitative analyses. They
identified 250 rapamycin-sensitive phosphorylation sites from 161
cellular proteins. Their main finding was the identification of
CDC25B (Ser375) as the key phosphorylation event in mediating
rapamycin-induced oncogenic Akt activation [48]. Huber et al.
[35] used Saccharomyces cerevisiae with various genetic back-
grounds for label-free quantitative phosphoproteomic screens.
This study reported 41 rapamycin-sensitive yeast proteins and
revealed that rapamycin-regulated Sch9 (a homolog of mamma-
lian kinases Akt and p70S6K1) is a central coordinator of protein
synthesis.
To our knowledge, our work represents the first in-depth, global
analysis of rapamycin-dependent phosphoproteomics performed
on whole tissue samples. One noteworthy result is the identifica-
tion of several rapamycin-sensitive candidates that are related to
translation. eIF3a is the largest component of the eIF3 complex,
which is required for several steps in the initiation of protein
synthesis [64]. The eIF3 complex interacts with p70S6K under
conditions of nutrient depletion or starvation [65]. We found that
rapamycin administration was associated with a marked reduction
in phosphorylation of a component of eIF3, eIF3a, at Ser584 in all
three animal sets. Although the function of this site has not been
defined, a search of the Minimotif Miner (http://mnm.engr.
uconn.edu/) database reveals that the [KR]xRxx[ST] consensus
motif is also present in ribosomal protein S6, a substrate for
p70S6K. Our observation is consistent with the hypothesis that
refeeding of rats after starvation causes the activation of
mTORC1, leading to phosphorylation and release of p70S6K
from the eIF3 complex.
We observed rapamycin-sensitive phosphorylation events in-
volving several other proteins associated with translation. Ribo-
nuclease UK114, also identified as ‘‘translational inhibitor protein
p14.5’’, has been shown in previous studies to be related to
inhibition of cell proliferation [66,67]. We found that rapamycin
administration was associated with a .5-fold increase in
phosphorylation of this protein at Thr10 and Ser11 in all three
paired analyses. These sites have not been previously identified or
characterized.
We also identified several known direct interactors of mTOR as
rapamycin-sensitive phosphoproteins. Among these were the
mTORC1 component raptor on Ser863 [49] and PRAS40, a
novel mTOR binding partner (53). Rapamycin has been shown to
decrease the association of PRAS40 with mTORC1 proteins (53),
an event for which the mechanism has not been elucidated. The














AKT1 substrate 1 (PRAS40) isoform CRA_d AKT1S1 S203 CK2a1 (123) CK2a2 (117) p70S6K (106) p70S6K (105) SRPK1 (97)
AKT1 substrate 1 (PRAS40) isoform CRA_d AKT1S1 S213 mTOR (247) PCTAIRE3 (220) PCTAIRE2 (214) PCTAIRE1 (202) ERK1 (200)
AMP-activated protein kinase alpha-2 PRKAA2 S377 mTOR (221) NLK (170) CDK1 (163) CDK3 (161) PCTAIRE3 (161)
Bcl2-associated athanogene 3 BAG3 S174 ATR (296) ATM (245) DNAPK (161) SRPK1 (106) SRPK2 (98)
Carbomyl-phosphate synthase 2 CAD S1859 ROCK2 (195) PIM1 (179) ROCK1 (177) MRCKb (171) DMPK1 (169)
Eukaryotic translation initiation factor 3A (ZH12
protein)
EIF3A S584 SGK2 (163) PIM1 (163) PKG1 (158) AKT2 (156) PIM3 (156)
Growth factor receptor binding protein 7 GRB7 S364 JNK1 (194) JNK2 (194) JNK3 (193) mTOR ( 184) MAPK14 (151)
Hepatoma-derived growth factor 3 (HDGF2) HDGFRP2 S450 PIM1 (259) PIM2 (256) PIM3 (256) p70S6K (249) p70S6Kb (249)
MAF1 (Repressor of RNA polymerase III
transcription)
MAF1 S75 ATR (309) ATM (250) DNAPK (135) CK2a1 (61) mTOR (55)
Peroxisome biogenesis factor 1 PEX1 S1181 ATR (343) ATM (275) PIM1 (172) PIM3 (172) PKG1 (169)
Protein kinase C beta II PRKCB S660 mTOR (136) ILK (98) MAPK12 (77) ERK1 (69) ERK2 (65)
PTPRF interacting protein (liprin) alpha 1 PPFIA1 S667 p70S6K (130) p70S6Kb (130) PIM2 (110) PIM1 (109) SGK (104)
Raptor RPTR S863 mTOR (293) PCTAIRE3 (267) PCTAIRE2 (263) PCTAIRE1 (250) CDK1 (232)
Ribosomal protein S6 RPS6 S235 PKCa (256) PKCb (244) ROCK2 (234) MRCKb (231) MRCKa (230)
Ribosomal protein S6 RPS6 S236 PIM1 (250) p70S6K (249) p70S6Kb (249) PIM3 (247) PIM2 (237)
Ribosomal protein S6 RPS6 S240 SRPK1 (162) SRPK2 (156) MSSK1 (151) MRCKb (117) MRCKa (116)
Sugen Kinase 269 (hypothetical protein
XP_236266)
RGD1312026S281 JNK2 (225) JNK3 (219) JNK1 (217) PFTK1 (215) MAPK14 (203)
Ubiquitin specific peptidase 15, isoform CRA_a USP15 S242 mTOR (178) ERK1 (155) ERK2 (155) PFTK1 (129) ERK5 (126)
Ubiquitin specific protease 24 USP24 S1138 ATR (44) ATM (42) GSK3B (38) PKACa (33) SgK085 (33)
*Shown are the 5 human protein kinases that are most likely to phosphorylate each of the designated phosphosites. Kinase prediction scores are shown in parentheses.
The higher the kinase prediction score, the better the prospect that a kinase will phosphorylate a given site.
doi:10.1371/journal.pone.0021729.t003
Phosphoproteomic Profiling of mTORC1 Signaling
PLoS ONE | www.plosone.org 10 June 2011 | Volume 6 | Issue 6 | e21729exact mechanism by which PRAS40 inhibits mTORC1 activity is
not well understood. We found that rapamycin treatment was
associated with reduced phosphorylation of rat PRAS40 at Ser203
and Ser213 in all three paired analyses. A recent phosphopeptide
mapping study identified Ser183, Ser212 and Ser221 as mTOR-
dependent phosphorylation sites in human PRAS40 [53]. Ser212
of human PRAS40, which is homologous to Ser213 in rat
PRAS40, was not identified as sensitive to rapamycin treatment by
these investigators.
AMPK is a critical sensor of metabolic stress that can turn off
biosynthetic pathways when cellular ATP/AMP ratios decline [68].
The two AMPkinaseisoforms,whichgenerallyfunctioninthesame
manner (53), can inhibit mTORC1 by phosphorylating and
activating TSC2. We detected a rapamycin-associated reduction
in phosphorylation of AMPK2 at Ser377 in all three paired
analyses. The Kinexus’ kinase predictor software indicated that
mTOR is a candidate kinase for this particular site. Our results may
indicate a feedback mechanism between mTOR and AMPK
through this rapamycin-sensitive phosphorylation event.
Gephyrin is a microtubule-associated protein involved in
membrane protein-cytoskeleton interactions that is purported to
directly interact with mTOR in a manner that is required for
rapamycin-sensitive signaling [54]. The underlying mechanism has
not been identified. We found that rapamycin administration was
associated with a .12-fold increase in phosphorylation of gephyrin
at Ser200, a site that has not been assigned a biological function.
Chen and coworkers detected more transcription-related
proteins (9.3%) than translation-related proteins (5.4%) among
their rapamycin-sensitive proteins [48], just as we did. However,
the only rapamycin-sensitive phosphorylation events common to
our dataset and theirs were the well-characterized ribosomal
protein S6 sites. An RNA binding protein, the La ribonucleopro-
tein (LARP), was identified as a rapamycin-sensitive candidate in
both studies. Phosphorylation of human LARP at Ser849, which is
homologous to Ser648 of rat LARP, was reduced upon rapamycin
exposure in the study by Chen et al. [48], while we observed an
increase in the phosphorylation of rat LARP at the Thr644 and
Ser648 sites in association with rapamycin administration. A
comparison of our data to those of Huber and coworkers [35]
shows that in both cases Maf1 and S6 were the only common
rapamycin-sensitive proteins previously reported in the literature.
While our approach allowed us to identify what may be novel,
physiologically relevant rapamycin-sensitive sites, our study has
some important limitations. One is incomplete coverage of any
given protein due to a suboptimal density of tryptic sites. For
example, lysine and arginine content within eIF4G1 is very high,
so digestion with trypsin results in very short peptide fragments.
This likely accounted for our inability to identify peptides
containing the rapamycin-sensitive Ser1108 phosphorylation site
in eIF4G1 [69]. Other established rapamycin-sensitive phosphor-
ylation sites include p70S6K (Thr389) and 4E-BP1 (Thr37) and
(Thr46) [70]. We do not have a definitive explanation for the
absence of p70S6K Thr389 in our analyses, though low
abundance of this phosphoprotein is likely. While we detected
the Thr37 and Thr46 phosphorylation sites in 4E-BP1, their
phosphorylation was not affected by rapamycin in either our study
or another published study [48]. This may be consistent with
recent biochemical studies indicating a complex mechanism
behind the effect of rapamycin on 4E-BP1 phosphorylation
[48,71,72].
There are other limitations inherent in our approach. We began
with a preparation of proteins that were soluble under aqueous,
non-detergent-containing conditions. Since the presence of
detergents in samples complicates MS analysis [73,74], extension
of our methods to lipid-soluble proteins may be challenging. Very
low abundance proteins or proteins with a low stoichiometry of
phosphorylation would not have been detected in our MS analysis
due to sensitivity limits of the LTQ-FTICR classic mass
spectrometer and the suppression of ionization efficiency with
the detection of phosphorylated peptides in the positive ion mode
[75]. These issues notwithstanding, we made another observation
of potential physiological significance. That was the high
frequency with which previously unidentified phosphorylation
sites were up-regulated in association with rapamycin administra-
tion. It is, of course, the case that rapamycin-sensitive phospho-
proteins may not be direct targets of mTOR kinase. The up-
regulation of phosphorylation in response to rapamycin can be
accounted for by a downstream kinase that is activated upon its
own dephosphorylation. An example of such a mechanism is
eukaryotic elongation factor 2 kinase (eEF2K), which is activated
in response to its dephosphorylation [76]. Alternatively, such
changes may reflect modulation of phosphatase activity.
Identification of potential rapamycin-sensitive phosphorylation
sites is only the first step in characterizing the signaling events we
have identified. The assignment of functional significance to newly
identified sites will require a traditional biochemical approach.
Nonetheless, through the application of a phosphoproteomics
approach to an in vivo model of mTORC1 signaling we have
identified 67 rapamycin-sensitive candidate phosphorylation
events. Identification of known rapamycin-sensitive phosphoryla-
tion sites supported the reliability of our analysis. We identified a
high number of novel rapamycin-sensitive candidate phosphory-
lation sites on proteins that are related to transcription, translation
or cell growth, or are known to interact with mTOR kinase. While
contributing to the understanding of mTOR action, our results
indicate the potential utility of phosphoproteomic profiling of in
vivo tissues in identifying new targets for drug therapies.
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